Rock Springs Capital is an SEC-registered investment adviser based in Baltimore, MD that reports managing 2 hedge funds on Form ADV. It reports $2.4 billion in regulatory assets under management. Its private funds, of all types, hold $2.4 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +15.4% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +54.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $2.4 billionForm ADV Item 5.F
- Gross assets of private funds
- $2.4 billionAll private fund types, Form ADV
- Hedge funds managed
- 22 private funds in total
- Employees
- 17Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 168648
- Latest Form ADV
- 03/24/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +20.2% | +14.8% |
| Q1 2026 | -3.9% | -4.6% |
| Q4 2025 | +17.5% | +2.4% |
| Q3 2025 | +17.8% | +7.8% |
| Q2 2025 | +7.2% | +10.4% |
| Q1 2025 | -7.7% | -4.5% |
| Q4 2024 | -6.3% | +2.1% |
| Q3 2024 | +4.4% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 107 share positions ($1,859,870,981) reported by Rock Springs Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Revolution Medicines Inc9.59%
- Travere Therapeutics Inc6.98%
- Eli Lilly & Co6.14%
- Madrigal Pharmaceuticals Inc4.80%
- Mirum Pharmaceuticals Inc3.58%
- Rhythm Pharmaceuticals Inc3.55%
- Kymera Therapeutics Inc2.46%
- Insmed Inc2.24%
- Unitedhealth Group Inc1.82%
- Scholar Rock Hldg Corp1.77%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Revolution Medicines Inc | $178,423,487 | 9.59% | 869,256 | -21.35% |
| Travere Therapeutics Inc | $129,776,525 | 6.98% | 2,204,085 | +1.15% |
| Eli Lilly & Co | $114,203,796 | 6.14% | 98,700 | Unchanged |
| Madrigal Pharmaceuticals Inc | $89,326,406 | 4.80% | 177,249 | +1.29% |
| Mirum Pharmaceuticals Inc | $66,656,449 | 3.58% | 779,790 | -2.30% |
| Rhythm Pharmaceuticals Inc | $65,945,719 | 3.55% | 692,598 | Unchanged |
| Kymera Therapeutics Inc | $45,792,649 | 2.46% | 409,631 | -9.60% |
| Insmed Inc | $41,689,635 | 2.24% | 365,250 | +0.86% |
| Unitedhealth Group Inc | $33,863,130 | 1.82% | 92,250 | +44.71% |
| Scholar Rock Hldg Corp | $32,985,841 | 1.77% | 682,654 | -4.58% |
| Ascendis Pharma A/s | $32,807,520 | 1.76% | 144,000 | -14.67% |
| Tenet Healthcare Corp | $31,945,000 | 1.72% | 125,000 | Unchanged |
| Minimed Group Inc | $31,249,350 | 1.68% | 1,605,000 | +5.59% |
| Irhythm Holdings Inc | $31,137,157 | 1.67% | 273,950 | +1.59% |
| Intuitive Surgical Inc | $29,379,018 | 1.58% | 72,250 | -5.51% |
| Argenx SE | $28,767,300 | 1.55% | 30,000 | -43.13% |
| Heartflow Inc | $28,606,250 | 1.54% | 575,000 | +0.26% |
| Dexcom Inc | $25,326,115 | 1.36% | 293,500 | -14.43% |
| Boston Scientific Corp | $23,352,750 | 1.26% | 535,000 | +1.23% |
| Tarsus Pharmaceuticals Inc | $22,413,440 | 1.21% | 285,122 | +2.90% |
| Amylyx Pharmaceuticals Inc | $22,022,123 | 1.18% | 756,774 | +51.43% |
| Celldex Therapeutics Inc New | $21,174,879 | 1.14% | 653,344 | -6.55% |
| Agilon Health Inc | $20,892,375 | 1.12% | 262,500 | Unchanged |
| Zai Lab LTD | $20,843,026 | 1.12% | 791,307 | -2.87% |
| Erasca Inc | $20,603,061 | 1.11% | 1,405,393 | +0.23% |
| Pharvaris N V | $20,565,123 | 1.11% | 648,333 | Unchanged |
| Structure Therapeutics Inc | $20,022,713 | 1.08% | 640,317 | Unchanged |
| Aclaris Therapeutics Inc | $19,941,275 | 1.07% | 3,791,117 | -12.46% |
| Xenon Pharmaceuticals Inc | $19,515,750 | 1.05% | 524,758 | -23.27% |
| Penumbra Inc | $19,100,400 | 1.03% | 60,000 | -48.16% |
| Avalyn Pharmaceuticals Inc | $18,886,534 | 1.02% | 662,918 | Unchanged |
| Parabilis Medicines Inc | $18,640,403 | 1.00% | 577,281 | -0.13% |
| Neurocrine Biosciences Inc | $18,510,120 | 1.00% | 130,500 | -9.84% |
| Enliven Therapeutics Inc | $18,045,329 | 0.97% | 393,659 | -15.27% |
| Hemab Therapeutics Hldgs Inc | $17,746,323 | 0.95% | 575,432 | Unchanged |
| Inspire Med SYS Inc | $16,923,840 | 0.91% | 244,000 | Unchanged |
| Danaher Corp Del | $16,904,265 | 0.91% | 76,300 | Unchanged |
| MBX Biosciences Inc | $16,140,841 | 0.87% | 275,347 | -7.67% |
| Omeros Corp | $16,130,802 | 0.87% | 847,206 | +17.91% |
| Agios Pharmaceuticals Inc | $15,705,139 | 0.84% | 472,335 | -11.31% |
| Newamsterdam Pharma Company | $14,931,069 | 0.80% | 613,942 | +5.35% |
| Dyne Therapeutics Inc | $14,368,010 | 0.77% | 891,869 | -5.34% |
| Ultragenyx Pharmaceutical In | $13,904,088 | 0.75% | 925,089 | -4.42% |
| Zenas Biopharma Inc | $13,541,017 | 0.73% | 502,077 | Unchanged |
| Caris Life Sciences Inc | $13,431,255 | 0.72% | 438,500 | -10.05% |
| Cytokinetics Inc | $13,303,208 | 0.72% | 201,839 | +7.37% |
| Bridgebio Pharma Inc | $12,650,050 | 0.68% | 192,250 | +32.82% |
| Cogent Biosciences Inc | $12,467,403 | 0.67% | 389,363 | -24.53% |
| Mineralys Therapeutics Inc | $12,186,819 | 0.66% | 484,951 | Unchanged |
| Summit Therapeutics Inc | $12,090,650 | 0.65% | 715,000 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 12 new positions, 9 sold out, 32 increased, 30 reduced and 33 unchanged.
Number of positions (a count, not dollars)
- New positions12
- Increased32
- Unchanged33
- Reduced30
- Sold out9
New positions
| Stock | Value | Shares |
|---|---|---|
| Latigo Biotherapeutics Inc | $10,930,100 | 654,497 |
| Freenome Inc | $10,666,215 | 677,220 |
| Abcellera Biologics Inc | $4,012,250 | 275,000 |
| Ionis Pharmaceuticals Inc | $2,924,575 | 65,500 |
| Teva Pharmaceutical Inds LTD | $2,445,300 | 61,750 |
| Immunovant Inc | $2,368,079 | 70,103 |
| Atea Pharmaceuticals Inc | $2,259,160 | 433,620 |
| Celcuity Inc | $2,028,794 | 25,513 |
| Climb Bio Inc | $1,335,808 | 116,461 |
| Humana Inc | $1,278,260 | 3,350 |
| Braveheart Bio Inc | $1,228,907 | 60,837 |
| Compass Pathways PLC | $295,798 | 23,778 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Medtronic PLC | $2,417,307 | 30,900 |
| Teva Pharmaceutical Inds LTD | $1,998,920 | 59,000 |
| Dianthus Therapeutics Inc | $1,981,378 | 20,326 |
| Altimmune Inc | $1,433,254 | 471,465 |
| Surgery Partners Inc | $1,411,200 | 84,000 |
| Oruka Therapeutics Inc | $1,146,894 | 12,051 |
| Viking Therapeutics Inc | $994,755 | 25,500 |
| Glaukos Corp | $663,860 | 4,750 |
| Moonlake Immunotherapeutics | $208,251 | 10,696 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Unitedhealth Group Inc | +28,500 | +44.71% | $33,863,130 | 92,250 |
| Amylyx Pharmaceuticals Inc | +257,010 | +51.43% | $22,022,123 | 756,774 |
| Bridgebio Pharma Inc | +47,500 | +32.82% | $12,650,050 | 192,250 |
| Omeros Corp | +128,707 | +17.91% | $16,130,802 | 847,206 |
| Novo-nordisk A S | +47,300 | +74.49% | $4,200,428 | 110,800 |
| Minimed Group Inc | +85,000 | +5.59% | $31,249,350 | 1,605,000 |
| Travere Therapeutics Inc | +25,016 | +1.15% | $129,776,525 | 2,204,085 |
| Spyre Therapeutics Inc | +15,292 | +36.19% | $5,123,320 | 57,546 |
| Neurogene Inc | +47,651 | +44.64% | $4,295,436 | 154,401 |
| Olema Pharmaceuticals Inc | +148,400 | +63.10% | $3,314,114 | 383,578 |
| Madrigal Pharmaceuticals Inc | +2,250 | +1.29% | $89,326,406 | 177,249 |
| Cytokinetics Inc | +13,859 | +7.37% | $13,303,208 | 201,839 |
| Stryker Corporation | +3,300 | +11.38% | $8,895,097 | 32,300 |
| Newamsterdam Pharma Company | +31,198 | +5.35% | $14,931,069 | 613,942 |
| Sagimet Biosciences Inc | +65,458 | +26.18% | $3,116,725 | 315,458 |
| Tarsus Pharmaceuticals Inc | +8,035 | +2.90% | $22,413,440 | 285,122 |
| Phreesia Inc | +51,600 | +7.40% | $7,732,005 | 748,500 |
| Irhythm Holdings Inc | +4,300 | +1.59% | $31,137,157 | 273,950 |
| Ardelyx Inc | +128,100 | +5.71% | $8,104,952 | 2,369,869 |
| Immunome Inc | +19,688 | +5.66% | $7,901,785 | 367,354 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Revolution Medicines Inc | -235,954 | -21.35% | $178,423,487 | 869,256 |
| Argenx SE | -22,750 | -43.13% | $28,767,300 | 30,000 |
| Penumbra Inc | -55,750 | -48.16% | $19,100,400 | 60,000 |
| Alnylam Pharmaceuticals Inc | -28,750 | -43.07% | $9,376,120 | 38,000 |
| Azenta Inc | -200,250 | -49.69% | $7,073,948 | 202,750 |
| Xenon Pharmaceuticals Inc | -159,149 | -23.27% | $19,515,750 | 524,758 |
| Ascendis Pharma A/s | -24,750 | -14.67% | $32,807,520 | 144,000 |
| Kymera Therapeutics Inc | -43,525 | -9.60% | $45,792,649 | 409,631 |
| Dexcom Inc | -49,500 | -14.43% | $25,326,115 | 293,500 |
| Cogent Biosciences Inc | -126,554 | -24.53% | $12,467,403 | 389,363 |
| Enliven Therapeutics Inc | -70,966 | -15.27% | $18,045,329 | 393,659 |
| Aclaris Therapeutics Inc | -539,415 | -12.46% | $19,941,275 | 3,791,117 |
| Omada Health Inc | -112,750 | -30.23% | $5,415,803 | 260,250 |
| Vera Therapeutics Inc | -71,378 | -16.69% | $11,501,892 | 356,206 |
| Neurocrine Biosciences Inc | -14,250 | -9.84% | $18,510,120 | 130,500 |
| Agios Pharmaceuticals Inc | -60,228 | -11.31% | $15,705,139 | 472,335 |
| Intuitive Surgical Inc | -4,210 | -5.51% | $29,379,018 | 72,250 |
| Arcus Biosciences Inc | -65,346 | -36.30% | $2,961,513 | 114,654 |
| Scholar Rock Hldg Corp | -32,798 | -4.58% | $32,985,841 | 682,654 |
| Mirum Pharmaceuticals Inc | -18,355 | -2.30% | $66,656,449 | 779,790 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (3)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures